Provider review
TrimRx tirzepatide review
What TrimRx charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
TrimRx is not scored on our v4.1 rubric: its home page returned no readable content on November 21, 2026, and the portfolio read of November 20 could not reach it.
What is distinctive about this programme
Flat rate, no membership — but check which rate
TrimRx is reported as flat at all doses with no membership fee, which is the structurally favourable combination. The complication is that it publishes several different figures for the same programme depending on billing.
For semaglutide: $179 first month then $299 ongoing on month-to-month, or $209 on three months prepaid, $191 on six, $174 on twelve. For tirzepatide: $279 first month then $399 ongoing, or $316, $299 and $283 on the prepay tiers.
So the ongoing month-to-month rate is roughly 70% above the twelve-month prepaid rate for semaglutide and 41% above for tirzepatide. The $179 and $279 figures are introductory and apply to one month.
Where it sits
At $283 on a twelve-month plan (July 2026), TrimRx’s tirzepatide was above Found ($169) and Oak Longevity ($199) in our July records, and NexLife now lists $115 to $129 (November 20, 2026). At $174, TrimRx’s semaglutide sat above NexLife’s current $95 to $109 and Found’s July $169.
Our dataset also notes that a previously stored TrimRx figure of $259 matched no current tier and was corrected — a useful illustration of why figures repeated across comparison sites need re-capture rather than reuse.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $199 | Provider-reported |
| Tirzepatide injectable | $349 | Provider-reported |
Where it holds up
- Flat rate at all doses with no membership fee
- Prepay tiers are clearly published at three, six and twelve months
- Competitive semaglutide pricing on the twelve-month tier
Where it does not
- Ongoing month-to-month rates are substantially above the prepaid tiers
- First-month figures are introductory and apply to one month only
- Tirzepatide pricing is above the market's lower band and close to brand at some tiers
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Flat across covered doses |
| Lowest captured figure | $199/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| TrimRx | month_to_month | compounded injectable | flat at all covered doses | $349 | $0 | $349 | Recurring | Provider-reported | 2026-07-06 |
| TrimRx | month_to_month | compounded injectable | flat at all covered doses | $199 | $0 | $199 | Recurring | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where TrimRx sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is TrimRx the cheapest option?
Not scored: its home page returned no readable content on November 21, 2026, and the portfolio read of November 20 could not reach it.
Is compounded tirzepatide the same as Zepbound?
No. Compounded tirzepatide is not FDA-approved, is not generic and is not the same product as Zepbound or Mounjaro; it is made with the drug in those products. Brand Zepbound bought through any platform is the FDA-approved product.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- How to Verify GLP-1 Claims in AI Search ResultsJournal
- How to Get Tirzepatide Online SafelyPillar / Money
- Henry Meds Tirzepatide ReviewProviders
Related coverage
GLP-1 Tirzepatide Review. “TrimRx Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/trimrx/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.